Travere Therapeutics (TVTX) Non-Current Assets (2013 - 2026)

Travere Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $162.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 6.94% year-over-year to $162.5 million; the trailing twelve-month figure through Mar 2026 stood at $673.3 million (down 5.68% YoY), and the FY2025 full-year result was $167.6 million, down 5.52% from the prior year.
• Non-Current Assets for Q1 2026 stood at $162.5 million, down from $167.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $203.3 million in Q1 2023, with the low at $146.6 million in Q3 2023.
• Historically, Non-Current Assets has averaged $179.6 million across 5 years, with a median of $179.7 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Assets fell 23.39% — and 2024, when it increased 22.54%.
• Travere Therapeutics' Non-Current Assets stood at $186.1 million in 2022, then declined by 7.53% to $172.1 million in 2023, then advanced by 3.07% to $177.4 million in 2024, then declined by 5.52% to $167.6 million in 2025, then dropped by 3.05% to $162.5 million in 2026.
• The last three Non-Current Assets figures came in at $162.5 million (Q1 2026), $167.6 million (Q4 2025), and $167.5 million (Q3 2025), per Business Quant data.